| Article | Date | Source |
|---|
| Durata Therapeutics plans $46 million stock offering | April 12, 2013 | Health News - BizJournals.com |
| Regulus slashes IPO price; Durata Therapeutics to move R&D to Connecticut; Black mamba venom contains powerful pain reliever; | October 04, 2012 | FierceBiotech |
| Durata Therapeutics, Inc. to Move to CT, 80 New Jobs Created | October 04, 2012 | BioSpace |
| Durata Therapeutics to move R&D to Connecticut; Black mamba venom contains powerful pain reliever; | October 04, 2012 | FierceBiotech |
| Durata Therapeutics to Present at 11th Annual BIO Investor Forum | October 03, 2012 | Pharma News - Business Wire |
| Durata Therapeutics, Inc. Announces Completion of QT Study of Dalbavancin | September 11, 2012 | BioSpace - Breaking News |
| Durata Therapeutics Announces Completion of QT Study of Dalbavancin | September 11, 2012 | Pharma News - Business Wire |
| New Data Demonstrating Potency of Durata Therapeutics’ Dalbavancin Against Bacterial Pathogens Presented at ICAAC 2012 | September 10, 2012 | Biotech News - Business Wire |
| Durata Therapeutics, Inc. Completes Target Enrollment in Phase 3 DISCOVER 1 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in abSSSI Patients | September 06, 2012 | BioSpace - Breaking News |
| Durata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 1 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in abSSSI Patients | September 06, 2012 | Pharma News - Business Wire |
| Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012 | August 29, 2012 | Pharma News - Business Wire |
| Durata rises; analyst bullish on antibiotic | August 14, 2012 | Health News - CNBC |
| Durata Therapeutics Adds Independent Director Lisa M. Giles to the Company’s Board | July 26, 2012 | Pharma News - Business Wire |
| Durata Therapeutics Becomes Second Completed IPO in Month | July 20, 2012 | Burrill Report |
| Durata Therapeutics, Inc. Prices $68 Million IPO | July 19, 2012 | BioSpace |
| Faded star at Pfizer leads to discounted $68M IPO for Durata | July 19, 2012 | FierceBiotech |
| Durata Therapeutics Prices Initial Public Offering | July 19, 2012 | Pharma News - Business Wire |
| St Jude says Durata lead wire hurt by external abrasion | June 22, 2012 | Health News - CNBC |
| St. Jude Medical Comments on MAUDE Database Report about Durata Lead | June 22, 2012 | FDA News - Business Wire |
| Durata Therapeutics, Inc. Files for $86 Million US IPO | March 23, 2012 | BioSpace |
| Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering | March 22, 2012 | Pharma News - Business Wire |
